An email from Pharmac this morning, if you’re in NZ please pass on your views. If not, well maybe pass them on too.
Pharmac consultation: proposal on access criteria for two COVID-19 treatments
Kia ora
Please follow this link to the Pharmac Consultation regarding proposed access criteria for nirmatrelvir with ritonavir (Paxlovid, Pfizer PF-07321332) and molnupiravir (Lageviro, MK-4482) for the treatment of COVID-19.
Pharmac welcomes feedback on this proposal.
To provide feedback, please email consult@pharmac.govt.nz by 5pm on Wednesday 2nd March 2022.
Please circulate this email to others who may be interested.
Ngā mihi nui
Ben Graham | Therapeutic Group Manager
____________________________________________________________________
PHARMAC | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington | P: +64 4 460 4990 | www.pharmac.govt.nz
I don't have the spare brain to research these treatments.
But instinct smells a rat.
I am not the sort to want to be first just to show off, well not for this sort of fashion.
But I will say that "they" have recently graduated from Marketing 101; and now know that perceived scarcity will create a demand.